Analysts Set Humacyte, Inc. (NASDAQ:HUMA) PT at $9.29

Key Points

• Humacyte, Inc. has received a consensus recommendation of "Moderate Buy" from seven ratings firms, with one hold and six buy ratings present.
• The average twelve-month price target among analysts is $9.2857, although some analysts have lowered their targets significantly.
• Insider activity reveals CEO Laura E. Niklason and Director Brady W. Dougan sold significant shares, totaling approximately $934,862 each, amidst a backdrop of recent hedge fund investments in the company.

Shares of Humacyte, Inc. (NASDAQ:HUMA - Get Free Report) have been assigned a consensus recommendation of "Moderate Buy" from the seven ratings firms that are presently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $9.2857.

A number of equities analysts recently issued reports on the stock. Barclays began coverage on shares of Humacyte in a research note on Wednesday, August 27th. They issued an "overweight" rating and a $3.50 price target on the stock. TD Cowen decreased their target price on shares of Humacyte from $5.00 to $3.50 and set a "buy" rating for the company in a report on Tuesday, August 12th. D. Boral Capital reiterated a "buy" rating and set a $25.00 price target on shares of Humacyte in a report on Monday, September 15th. HC Wainwright reduced their price target on shares of Humacyte from $4.00 to $3.00 and set a "buy" rating for the company in a research report on Tuesday, August 12th. Finally, Wall Street Zen cut Humacyte from a "hold" rating to a "sell" rating in a research report on Sunday, August 17th.

Insiders Place Their Bets

In related news, CEO Laura E. Niklason sold 1,100,000 shares of the stock in a transaction on Tuesday, August 19th. The stock was sold at an average price of $1.63, for a total transaction of $1,793,000.00. Following the sale, the chief executive officer directly owned 591,685 shares of the company's stock, valued at $964,446.55. This trade represents a 65.02% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Brady W. Dougan sold 1,100,000 shares of Humacyte stock in a transaction dated Tuesday, August 19th. The stock was sold at an average price of $1.63, for a total value of $1,793,000.00. Following the completion of the sale, the director owned 591,685 shares of the company's stock, valued at $964,446.55. The trade was a 65.02% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 4,482,090 shares of company stock worth $7,466,382. Corporate insiders own 5.10% of the company's stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Monashee Investment Management LLC bought a new stake in Humacyte in the 1st quarter worth approximately $3,410,000. Polar Asset Management Partners Inc. purchased a new position in shares of Humacyte in the 1st quarter worth $852,000. Woodline Partners LP boosted its stake in shares of Humacyte by 38.7% in the 1st quarter. Woodline Partners LP now owns 3,950,000 shares of the company's stock worth $6,735,000 after buying an additional 1,101,198 shares during the last quarter. ProShare Advisors LLC grew its holdings in shares of Humacyte by 30.4% in the fourth quarter. ProShare Advisors LLC now owns 30,852 shares of the company's stock worth $156,000 after acquiring an additional 7,188 shares during the period. Finally, Nuveen LLC purchased a new stake in Humacyte during the first quarter valued at $502,000. Institutional investors own 44.71% of the company's stock.

Humacyte Stock Down 0.8%

Shares of Humacyte stock traded down $0.02 during midday trading on Friday, hitting $1.76. The company had a trading volume of 1,053,783 shares, compared to its average volume of 3,944,985. Humacyte has a 52-week low of $1.15 and a 52-week high of $6.77. The company has a debt-to-equity ratio of 2.97, a quick ratio of 1.93 and a current ratio of 2.45. The stock has a market capitalization of $277.94 million, a P/E ratio of -3.90 and a beta of 1.88. The company has a 50 day moving average of $1.91 and a 200 day moving average of $2.04.

Humacyte (NASDAQ:HUMA - Get Free Report) last released its earnings results on Monday, August 11th. The company reported ($0.24) EPS for the quarter, missing the consensus estimate of ($0.15) by ($0.09). The business had revenue of $0.30 million during the quarter, compared to analyst estimates of $0.94 million. On average, equities analysts predict that Humacyte will post -1.27 earnings per share for the current fiscal year.

Humacyte Company Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.